Illumina, Inc. vs Materials Select Sector SPDR Fund — how do they compare? Illumina, Inc. trades at $265.01 (market cap $39.95B), while Materials Select Sector SPDR Fund trades at $49.45 (market cap $7.73B). The key difference: Illumina, Inc. is far larger — about 5.2× Materials Select Sector SPDR Fund's market cap, and Illumina, Inc. is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| ILMN | XLB | |
|---|---|---|
Market Cap | $39.95B | $7.73B |
Volume | 3,169,503 | 13,681,146 |
Sector | Health | — |
52-Week High | $293.69 | $53.67 |
52-Week Low | $91.00 | $42.23 |
Typical Hold Time | 83 Days | 70 Days |
Enterprise Value | $41.31B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
XLB, the Materials Select Sector SPDR ETF, trades at $48.98, down 1.51% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX signaling strong selling pressure. The ETF's portfolio is heavily concentrated in chemicals (49% of assets), and recent news highlights sector volatility amid broader market challenges outside of tech. A dividend of $0.23 is scheduled for September 2026, but financial ratios are currently unavailable.
The outlook for XLB is cautious due to technical weakness and sector cyclicality, though long-term infrastructure and AI-related demand offer potential upside. Risks include economic sensitivity and high concentration, while investor sentiment remains mixed with some analysts seeing value in materials as an AI-resistant play.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →